Last 12 months
Inside the activity.
0 purchase rows · 40 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2026 Filed Feb 3, 2026 23:05 UTC |
Cooke JulieChief Human Resources Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001776977-26-000005 · wk-form4_1770159920.xml · derivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,741 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 1,740 shares on January 31, 2023, vested as to 1,740 shares on January 31, 2024, vested as to 1,740 shares on January 31, 2025, and vested as to 1,741 shares on January 31, 2026, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 1,740 shares on January 31, 2023, vested as to 1,740 shares on January 31, 2024, vested as to 1,740 shares on January 31, 2025, and vested as to 1,741 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:05 UTC |
Cooke JulieChief Human Resources Officer
|
Tax withholdingCommon Stock | 997 | $136.06 | $135,651.82 |
DisclosureSEC source: 0001776977-26-000005 · wk-form4_1770159920.xml · nonDerivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,602 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. F2 · balance_after: 25,738 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:05 UTC |
Cooke JulieChief Human Resources Officer
|
Exercise / conversionCommon Stock | 1,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001776977-26-000005 · wk-form4_1770159920.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:04 UTC |
Delaet IngridChief Regulatory Officer
|
Exercise / conversionRestriced Stock Unit · Derivative | 801 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000003 · wk-form4_1770159888.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 801 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 800 shares on January 31, 2023, vested as to 800 shares on January 31, 2024, vested as to 801 shares on January 31, 2025, and vested as to 801 shares on January 31, 2026, subject to the terms and conditions of the award. F3 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 800 shares on January 31, 2023, vested as to 800 shares on January 31, 2024, vested as to 801 shares on January 31, 2025, and vested as to 801 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:04 UTC |
Delaet IngridChief Regulatory Officer
|
Tax withholdingCommon Stock | 475 | $136.06 | $64,628.50 |
DisclosureSEC source: 0001965808-26-000003 · wk-form4_1770159888.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,056 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:04 UTC |
Delaet IngridChief Regulatory Officer
|
Exercise / conversionCommon Stock | 801 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000003 · wk-form4_1770159888.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:03 UTC |
Gano KyleDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000005 · wk-form4_1770159832.xml · derivative · entry 3 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,927 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,926 shares on January 31, 2023, vested as to 2,926 shares on January 31, 2024, vested as to 2,927 shares on January 31, 2025, and vested as to 2,927 shares on January 31, 2026, subject to the terms and conditions of the award. F3 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,926 shares on January 31, 2023, vested as to 2,926 shares on January 31, 2024, vested as to 2,927 shares on January 31, 2025, and vested as to 2,927 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:03 UTC |
Gano KyleDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 1,580 | $136.06 | $214,974.80 |
DisclosureSEC source: 0001567160-26-000005 · wk-form4_1770159832.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,754 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:03 UTC |
Gano KyleDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000005 · wk-form4_1770159832.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:02 UTC |
GORMAN KEVIN CHARLESDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001201096-26-000003 · wk-form4_1770159750.xml · derivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and vested as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and vested as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:02 UTC |
GORMAN KEVIN CHARLESDirector
|
Tax withholdingCommon Stock | 2,845 | $136.06 | $387,090.70 |
DisclosureSEC source: 0001201096-26-000003 · wk-form4_1770159750.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,893 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. F2 · balance_after: 516,893 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:02 UTC |
GORMAN KEVIN CHARLESDirector
|
Exercise / conversionCommon Stock | 5,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001201096-26-000003 · wk-form4_1770159750.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:01 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001504783-26-000007 · wk-form4_1770159705.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,373 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,373 shares on January 31, 2023, vested as to 2,373 shares on January 31, 2024, vested as to 2,373 shares on January 31, 2025, and vested as to 2,373 shares on January 31, 2026, subject to the terms and conditions of the award. F3 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,373 shares on January 31, 2023, vested as to 2,373 shares on January 31, 2024, vested as to 2,373 shares on January 31, 2025, and vested as to 2,373 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:01 UTC |
Lippoldt DarinChief Legal Officer
|
Tax withholdingCommon Stock | 1,335 | $136.06 | $181,640.10 |
DisclosureSEC source: 0001504783-26-000007 · wk-form4_1770159705.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,792 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:01 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionCommon Stock | 2,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001504783-26-000007 · wk-form4_1770159705.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:01 UTC |
Onyia JudeChief Scientific Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 238 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000003 · wk-form4_1770159672.xml · derivative · entry 3 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 238 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 237 shares on January 31, 2023, vested as to 237 shares on January 31, 2024, vested as to 238 shares on January 31, 2025, and vested as to 238 shares on January 31, 2026, subject to the terms and conditions of the award. F3 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 237 shares on January 31, 2023, vested as to 237 shares on January 31, 2024, vested as to 238 shares on January 31, 2025, and vested as to 238 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:01 UTC |
Onyia JudeChief Scientific Officer
|
Tax withholdingCommon Stock | 142 | $136.06 | $19,320.52 |
DisclosureSEC source: 0001894425-26-000003 · wk-form4_1770159672.xml · nonDerivative · entry 2 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,977 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:01 UTC |
Onyia JudeChief Scientific Officer
|
Exercise / conversionCommon Stock | 238 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000003 · wk-form4_1770159672.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 23:56 UTC |
Gano KyleDirector · Chief Executive Officer
|
Exercise / conversionIncentive Stock Option · Derivative | 1,812 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001567160-26-000002 · wk-form4_1768953377.xml · derivative · entry 6 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,812 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 23:56 UTC |
Gano KyleDirector · Chief Executive Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 34,588 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001567160-26-000002 · wk-form4_1768953377.xml · derivative · entry 5 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,588 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 23:56 UTC |
Gano KyleDirector · Chief Executive Officer
|
SaleCommon Stock | 1,812 | $132.71 | $240,478.31 |
DisclosureSEC source: 0001567160-26-000002 · wk-form4_1768953377.xml · nonDerivative · entry 4 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,407 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.49 to $133.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 23:56 UTC |
Gano KyleDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 1,812 | $35.99 | $65,213.88 |
DisclosureSEC source: 0001567160-26-000002 · wk-form4_1768953377.xml · nonDerivative · entry 3 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 23:56 UTC |
Gano KyleDirector · Chief Executive Officer
|
SaleCommon Stock | 34,588 | $132.70 | $4,589,979.79 |
DisclosureSEC source: 0001567160-26-000002 · wk-form4_1768953377.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,407 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.42 to $133.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 23:56 UTC |
Gano KyleDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 34,588 | $35.99 | $1,244,822.12 |
DisclosureSEC source: 0001567160-26-000002 · wk-form4_1768953377.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 21:18 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionIncentive Stock Option · Derivative | 3,349 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001504783-26-000004 · wk-form4_1768252668.xml · derivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,349 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted February 5, 2016 and vested monthly over four years. These options were due to expire on February 5, 2026. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 21:18 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionCommon Stock | 3,349 | $35.99 | $120,530.51 |
DisclosureSEC source: 0001504783-26-000004 · wk-form4_1768252668.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 21:24 UTC |
Norwalk Leslie VDirector
|
SaleCommon Stock | 1,190 | $155.09 | $184,558.41 |
DisclosureSEC source: 0001533568-25-000007 · wk-form4_1766006643.xml · nonDerivative · entry 4 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,239 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.09 to $155.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:24 UTC |
Norwalk Leslie VDirector
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 1,724 | $0.00 Strike: $84.95 | $0.00 |
DisclosureSEC source: 0001533568-25-000007 · wk-form4_1766006643.xml · derivative · entry 6 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,724 shares Expires 2032-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on May 18, 2022 and vested in 12 equal monthly installments beginning June 18, 2022. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:24 UTC |
Norwalk Leslie VDirector
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 8,276 | $0.00 Strike: $92.35 | $0.00 |
DisclosureSEC source: 0001533568-25-000007 · wk-form4_1766006643.xml · derivative · entry 5 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 557 Underlying: Common Stock · 8,276 shares Expires 2031-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on May 19, 2021 and vested in 12 equal monthly installments beginning June 19, 2021. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:24 UTC |
Norwalk Leslie VDirector
|
SaleCommon Stock | 5,000 | $152.23 | $761,143.50 |
DisclosureSEC source: 0001533568-25-000007 · wk-form4_1766006643.xml · nonDerivative · entry 3 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,429 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.79 to $152.82. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:24 UTC |
Norwalk Leslie VDirector
|
Exercise / conversionCommon Stock | 1,724 | $84.95 | $146,453.80 |
DisclosureSEC source: 0001533568-25-000007 · wk-form4_1766006643.xml · nonDerivative · entry 2 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:24 UTC |
Norwalk Leslie VDirector
|
Exercise / conversionCommon Stock | 8,276 | $92.35 | $764,288.60 |
DisclosureSEC source: 0001533568-25-000007 · wk-form4_1766006643.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 14:04 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 4,376 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001504783-25-000006 · wk-form4_1765375469.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,376 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted February 6, 2017 and vested monthly over four years. These options were due to expire on February 6, 2027. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 14:04 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 4,376 | $159.65 | $698,615.27 |
DisclosureSEC source: 0001504783-25-000006 · wk-form4_1765375469.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,405 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $159.50 to $159.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 14:04 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionCommon Stock | 4,376 | $43.24 | $189,218.24 |
DisclosureSEC source: 0001504783-25-000006 · wk-form4_1765375469.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:14 UTC |
LYONS GARY ADirector
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $0.00 Strike: $47.89 | $0.00 |
DisclosureSEC source: 0001123343-25-000006 · wk-form4_1764882842.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options were due to expire on May 20, 2026. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:14 UTC |
LYONS GARY ADirector
|
SaleCommon Stock | 15,000 | $152.61 | $2,289,082.50 |
DisclosureSEC source: 0001123343-25-000006 · wk-form4_1764882842.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,482 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.63 to $154.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.direct: 114,499 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:14 UTC |
LYONS GARY ADirector
|
Exercise / conversionCommon Stock | 15,000 | $47.89 | $718,350.00 |
DisclosureSEC source: 0001123343-25-000006 · wk-form4_1764882842.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2025 Filed Dec 2, 2025 22:14 UTC |
Onyia JudeChief Scientific Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-25-000010 · wk-form4_1764713695.xml · derivative · entry 3 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,426 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F3 · derivative.exercise_date: This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and vested as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award. F3 · derivative.expiration_date: This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and vested as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award. Read SEC document |
| November 29, 2025 Filed Dec 2, 2025 22:14 UTC |
Onyia JudeChief Scientific Officer
|
Tax withholdingCommon Stock | 2,248 | $152.16 | $342,055.68 |
DisclosureSEC source: 0001894425-25-000010 · wk-form4_1764713695.xml · nonDerivative · entry 2 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,881 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| November 29, 2025 Filed Dec 2, 2025 22:14 UTC |
Onyia JudeChief Scientific Officer
|
Exercise / conversionCommon Stock | 4,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-25-000010 · wk-form4_1764713695.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,129 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 22:21 UTC |
BENEVICH ERICChief Commercial Officer
|
Exercise / conversionIncentive Stock Option · Derivative | 5,970 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001643653-25-000007 · wk-form4_1764714101.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,860 Underlying: Common Stock · 5,970 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 22:21 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 5,970 | $151.74 | $905,880.64 |
DisclosureSEC source: 0001643653-25-000007 · wk-form4_1764714101.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,893 F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.70 to $153.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 22:21 UTC |
BENEVICH ERICChief Commercial Officer
|
Exercise / conversionCommon Stock | 5,970 | $35.99 | $214,860.30 |
DisclosureSEC source: 0001643653-25-000007 · wk-form4_1764714101.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| November 28, 2025 Filed Jan 16, 2026 22:17 UTC Amendment |
BENEVICH ERICChief Commercial Officer
|
Exercise / conversionIncentive Stock Option · Derivative | 12,830 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001643653-26-000005 · wk-form4a_1768601876.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,830 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This Form 4 is being amended to correct the reporting of the Reporting Persons November 28, 2025 transaction. Due to an administrative error, the original Form 4 inadvertently reported the exercise of 5,970 stock options. The transaction actually consisted of the exercise of 12,830 stock options. F4 · derivative.exercise_date: The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026. Read SEC document |
| November 28, 2025 Filed Jan 16, 2026 22:17 UTC Amendment |
BENEVICH ERICChief Commercial Officer
|
Exercise / conversionCommon Stock | 12,830 | $35.99 | $461,751.70 |
DisclosureSEC source: 0001643653-26-000005 · wk-form4a_1768601876.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This Form 4 is being amended to correct the reporting of the Reporting Persons November 28, 2025 transaction. Due to an administrative error, the original Form 4 inadvertently reported the exercise of 5,970 stock options. The transaction actually consisted of the exercise of 12,830 stock options. F2 · balance_after: Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:28 UTC |
MORROW GEORGE JDirector
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $0.00 Strike: $47.89 | $0.00 |
DisclosureSEC source: 0001068754-25-000006 · wk-form4_1764192478.xml · derivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options were due to expire on May 20, 2026. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:28 UTC |
MORROW GEORGE JDirector
|
SaleCommon Stock | 15,000 | $143.37 | $2,150,512.50 |
DisclosureSEC source: 0001068754-25-000006 · wk-form4_1764192478.xml · nonDerivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,068 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.51 to $144.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:28 UTC |
MORROW GEORGE JDirector
|
Exercise / conversionCommon Stock | 15,000 | $47.89 | $718,350.00 |
DisclosureSEC source: 0001068754-25-000006 · wk-form4_1764192478.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 22:25 UTC |
RASTETTER WILLIAM HDirector
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 18,000 | $0.00 Strike: $47.89 | $0.00 |
DisclosureSEC source: 0001205903-25-000005 · wk-form4_1762467929.xml · derivative · entry 3 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2026-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options were due to expire on May 20, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.